← 홈

Antibody · 폐암 (NSCLC)

205개 · ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 205개
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 695상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
AntibodyHotstaleEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5
효능 ORR 70.6%임상시험 166상태 ACTIVE
AntibodyAHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5
효능 ORR 74%임상시험 123상태 ACTIVE
AntibodyCHotXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5
효능 ORR 76.7%임상시험 88상태 ACTIVE
AntibodyBstaleEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyARocheGovitecanPhase 3

carboplatin-etoposide (Atezolizumab + chemotherapy, Atezolizumab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 83상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodyMerckvedotin after avelumabPhase 1

pembrolizumab (Keytruda, Pembrolizumab (+) Berahyaluronidase alfa)

Advanced or Metastatic Solid Tumors · Metastatic Non-small Cell Lung Cancer

#MetastaticNon-smallCellLungCance#Antibody#Phase1#인기#항체+5
효능 ORR 65.1%임상시험 63상태 ACTIVE
AntibodyAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Tremelimumab)

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC · Malignant Solid Neoplasms

#MalignantSolidNeoplasms#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 62상태 ACTIVE
AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4
효능 ORR 77.8%임상시험 60상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 56상태 RECRUITING
AntibodyJiangsu Hansoh Pharmaceutical C…vedotin (RC48) in combinati…Phase 2

adebrelimab and chemotherapy (adebrelimab and chemotherapy)

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer · Efficacy and Safety of Neoadjuvant Immun

#EfficacyandSafetyofNeoadjuvantIm#Antibody#Phase2#인기#항체+5
임상시험 54상태 RECRUITING
AntibodyJanssenderuxtecan, datopotamab der…Phase 3

Amivantamab (Amivantamab)

Carcinoma, Non-Small-Cell Lung · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+5
효능 ORR 4.3%임상시험 51상태 RECRUITING
AntibodyRocheatApproved

bevacizumab [Avastin] (bevacizumab [Avastin])

Non-Squamous Non-Small Cell Lung Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Approved#항체#면역항체+5
효능 ORR 83%임상시험 43상태 ACTIVE
AntibodyRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+5
임상시험 39상태 RECRUITING
AntibodyGlaxoSmithKlinesPhase 3

Tarlatamab (Tarlatamab)

Neoplasms · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+4
효능 ORR 57.1%임상시험 36상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 77.8%임상시험 32상태 RECRUITING

1 / 11 페이지

← 이전다음 →